| Primary |
| Product Used For Unknown Indication |
100.0% |
|
|
| Secondary |
| Drug Use For Unknown Indication |
48.2% |
| Product Used For Unknown Indication |
20.2% |
| Sleep Disorder |
6.1% |
| Hallucination |
4.4% |
| Depression |
2.6% |
| Neurosis |
2.6% |
| Anxiety |
1.8% |
| Generalised Anxiety Disorder |
1.8% |
| Infection |
1.8% |
| Mental Disorder |
1.8% |
| Neuralgia |
1.8% |
| Psychotic Disorder |
1.8% |
| Atrial Fibrillation |
0.9% |
| Delusional Disorder, Persecutory Type |
0.9% |
| Epilepsy |
0.9% |
| Ill-defined Disorder |
0.9% |
| Renal Failure |
0.9% |
| Sexual Dysfunction |
0.9% |
|
| Sexual Dysfunction |
12.5% |
| Loss Of Consciousness |
9.4% |
| Toxicity To Various Agents |
9.4% |
| Maternal Exposure During Pregnancy |
6.3% |
| Overdose |
6.3% |
| Rash |
6.3% |
| Respiratory Depression |
6.3% |
| Talipes |
6.3% |
| Blood Creatinine Increased |
3.1% |
| Bone Disorder |
3.1% |
| Confusional State |
3.1% |
| Drug Toxicity |
3.1% |
| Drug Withdrawal Syndrome |
3.1% |
| Dystonia |
3.1% |
| Erythema Multiforme |
3.1% |
| Fall |
3.1% |
| Fatigue |
3.1% |
| Parkinsonism |
3.1% |
| Peripheral Sensory Neuropathy |
3.1% |
| Priapism |
3.1% |
|
| Concomitant |
| Drug Use For Unknown Indication |
19.3% |
| Product Used For Unknown Indication |
16.7% |
| Depression |
9.3% |
| Sleep Disorder |
8.7% |
| Hypertension |
4.7% |
| Non-small Cell Lung Cancer |
4.0% |
| Pain |
4.0% |
| Schizophrenia |
3.8% |
| Essential Hypertension |
3.6% |
| Asthma |
3.3% |
| Anxiety |
3.1% |
| Headache |
3.1% |
| Insomnia |
2.7% |
| Neuralgia |
2.4% |
| Blood Follicle Stimulating Hormone Decreased |
2.0% |
| Blood Luteinising Hormone Decreased |
2.0% |
| Hepatitis |
2.0% |
| Attention Deficit/hyperactivity Disorder |
1.8% |
| Gastrointestinal Stromal Tumour |
1.8% |
| Growth Hormone Deficiency |
1.8% |
|
| Pneumonia |
16.0% |
| Thrombosis |
8.0% |
| Muscle Spasms |
5.3% |
| Pyrexia |
5.3% |
| Renal Failure |
5.3% |
| Abscess |
4.0% |
| Congestive Cardiomyopathy |
4.0% |
| Dizziness |
4.0% |
| Epistaxis |
4.0% |
| Gastric Ulcer |
4.0% |
| Hypertension |
4.0% |
| Hypotension |
4.0% |
| Lung Disorder |
4.0% |
| Myocardial Infarction |
4.0% |
| Product Quality Issue |
4.0% |
| Sexual Dysfunction |
4.0% |
| Tachycardia |
4.0% |
| Torsade De Pointes |
4.0% |
| Treatment Noncompliance |
4.0% |
| Vascular Occlusion |
4.0% |
|
